{'fraction_non_alphanumeric': 0.029556650246305417, 'fraction_numerical': 0.014778325123152709, 'mean_word_length': 4.865384615384615, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of Gout

IN RESPONSE: Our search identified the randomized controlled trial of pegloticase (1). However, we excluded it because our review focused on the management of gout in primary care and pegloticase was considered to be a drug that primary care physicians do not use. We included Becker and colleagues' article (2) in both the review (reference 91) and the evidence report (reference 118). In that study, a post hoc analysis revealed the association between serum urate level achieved and reduction in tophi size achieved at week 52; we therefore did not consider it to be hypothesis-testing.